JOP20190183B1 - معدِلات مستقبلات الاستروجين - Google Patents

معدِلات مستقبلات الاستروجين

Info

Publication number
JOP20190183B1
JOP20190183B1 JOP/2019/0183A JOP20190183A JOP20190183B1 JO P20190183 B1 JOP20190183 B1 JO P20190183B1 JO P20190183 A JOP20190183 A JO P20190183A JO P20190183 B1 JOP20190183 B1 JO P20190183B1
Authority
JO
Jordan
Prior art keywords
estrogen receptor
receptor modulators
compounds
processes
formula
Prior art date
Application number
JOP/2019/0183A
Other languages
English (en)
Inventor
Bernard Christophe Barlaam
James Stewart Scott
Thomas Andrew MOSS
Johannes Wilhelmus Maria Nissink
Samantha Jayne HUGHES
Bin Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of JOP20190183A1 publication Critical patent/JOP20190183A1/ar
Application granted granted Critical
Publication of JOP20190183B1 publication Critical patent/JOP20190183B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات بالصيغة (I) صورة (I) وبأملاح مقبولة صيدلانياً منها، بعمليات ومركبات وسيطة تستخدم لتحضيرها، بتركيبات صيدلانية تحتوي عليها وباستخدامها في معالجة اضطرابات التكاثر الخلوي. الصيغة I
JOP/2019/0183A 2017-01-30 2018-01-29 معدِلات مستقبلات الاستروجين JOP20190183B1 (ar)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762451971P 2017-01-30 2017-01-30
US201762523695P 2017-06-22 2017-06-22
US201762560304P 2017-09-19 2017-09-19
US201762592485P 2017-11-30 2017-11-30
PCT/EP2018/052040 WO2018138303A1 (en) 2017-01-30 2018-01-29 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
JOP20190183A1 JOP20190183A1 (ar) 2019-07-28
JOP20190183B1 true JOP20190183B1 (ar) 2022-09-15

Family

ID=61223883

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0183A JOP20190183B1 (ar) 2017-01-30 2018-01-29 معدِلات مستقبلات الاستروجين

Country Status (36)

Country Link
US (3) US10221173B2 (ar)
EP (2) EP3689873B1 (ar)
JP (1) JP6951451B2 (ar)
KR (1) KR102246668B1 (ar)
CN (1) CN110214140B (ar)
AU (1) AU2018211495B2 (ar)
BR (1) BR112019015389A2 (ar)
CA (1) CA3050337A1 (ar)
CL (1) CL2019001991A1 (ar)
CO (1) CO2019008941A2 (ar)
CR (1) CR20190379A (ar)
CY (1) CY1122731T1 (ar)
DK (1) DK3494116T3 (ar)
DO (1) DOP2019000183A (ar)
EC (1) ECSP19062381A (ar)
ES (2) ES2931320T3 (ar)
HU (1) HUE047761T2 (ar)
IL (1) IL268263B (ar)
JO (1) JOP20190183B1 (ar)
LT (1) LT3494116T (ar)
MA (1) MA52555A (ar)
MX (1) MX2019008438A (ar)
MY (1) MY196317A (ar)
NI (1) NI201900080A (ar)
PE (1) PE20191500A1 (ar)
PH (1) PH12019501724A1 (ar)
PL (1) PL3494116T3 (ar)
PT (1) PT3494116T (ar)
RS (1) RS59770B1 (ar)
SG (1) SG11201906767XA (ar)
SI (1) SI3494116T1 (ar)
TN (1) TN2020000009A1 (ar)
TW (1) TWI794205B (ar)
UA (1) UA125043C2 (ar)
WO (1) WO2018138303A1 (ar)
ZA (1) ZA201904696B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3411034T3 (da) 2016-02-05 2021-01-11 Inventisbio Inc Selektiv østrogenreceptornedbrydere og anvendelser deraf
EP4086256A1 (en) 2016-12-16 2022-11-09 Janssen Pharmaceutica NV Small molecule inhibitors of the jak family of kinases
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
TW202126299A (zh) * 2019-09-19 2021-07-16 美商托特斯藥品公司 治療性共軛物
CN115557920B (zh) * 2022-09-22 2024-02-20 吉林奥来德光电材料股份有限公司 一种发光辅助材料、其制备方法及有机电致发光器件

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
MXPA03001169A (es) 2000-08-10 2003-06-30 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos.
WO2005111208A1 (ja) * 2004-04-27 2005-11-24 Chugai Seiyaku Kabushiki Kaisha プラズマ細胞の増殖方法
WO2006101434A1 (en) 2005-03-22 2006-09-28 Astrazeneca Ab NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
JP2010505961A (ja) 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US20120157402A1 (en) * 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
CA2763485C (en) 2009-05-27 2018-05-15 Neil Almstead Methods for treating cancer and non-neoplastic conditions
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
ES2654161T3 (es) * 2013-05-28 2018-02-12 Astrazeneca Ab Compuestos químicos
EP3010501B1 (en) 2013-06-19 2021-11-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JP6807841B2 (ja) 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーター及びその使用
PT3233852T (pt) 2014-12-18 2020-09-10 Hoffmann La Roche Tetrahidro-pirido[3,4-b]indóis como moduladores do recetor de estrogénio e suas utilizações
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
EP3303326B1 (en) 2015-05-26 2020-12-16 H. Hoffnabb-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
MX2017016376A (es) 2015-06-16 2018-03-02 Jiangsu Hengrui Medicine Co Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
JP6776348B2 (ja) 2015-10-01 2020-10-28 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途
CA3011391C (en) 2015-11-12 2021-02-09 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
BR112018011817A2 (pt) 2015-12-22 2018-12-04 Jiangsu Hengrui Medicine Co derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo
WO2017174757A1 (en) 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
CN109415388A (zh) 2016-05-06 2019-03-01 路易斯安那泽维尔大学 选择性雌激素受体下调剂(serds)
CN109415361B (zh) 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
EP4086256A1 (en) 2016-12-16 2022-11-09 Janssen Pharmaceutica NV Small molecule inhibitors of the jak family of kinases
UA123640C2 (uk) 2016-12-16 2021-05-05 Елі Ліллі Енд Компані Сполука 7-фенілетиламіно-4н-піримідо[4,5-d][1,3]оксазин-2-ону (варіанти) як інгібітор мутантів idh1 та idh2
CU24573B1 (es) 2016-12-16 2022-01-13 Pfizer Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
MX2019007120A (es) 2016-12-16 2019-09-16 Basf Se Compuestos plaguicidas.
MY195588A (en) 2017-01-30 2023-02-02 Chiesi Farm Spa Tyrosine Amide Derivatives As Rho- Kinase Inhibitors

Also Published As

Publication number Publication date
MX2019008438A (es) 2019-10-30
DK3494116T3 (da) 2020-01-27
MY196317A (en) 2023-03-24
CO2019008941A2 (es) 2019-08-30
CY1122731T1 (el) 2021-05-05
MA52555A (fr) 2021-03-17
JOP20190183A1 (ar) 2019-07-28
ES2931320T3 (es) 2022-12-28
US20180282325A1 (en) 2018-10-04
HUE047761T2 (hu) 2020-05-28
WO2018138303A1 (en) 2018-08-02
EP3494116A1 (en) 2019-06-12
CN110214140B (zh) 2022-08-30
PT3494116T (pt) 2020-01-28
RS59770B1 (sr) 2020-02-28
TW201840558A (zh) 2018-11-16
NI201900080A (es) 2020-03-18
CN110214140A (zh) 2019-09-06
US20200239468A1 (en) 2020-07-30
SI3494116T1 (sl) 2020-02-28
JP2020505354A (ja) 2020-02-20
EP3689873B1 (en) 2022-09-14
IL268263A (en) 2019-09-26
EP3494116B1 (en) 2019-10-23
KR102246668B1 (ko) 2021-04-29
DOP2019000183A (es) 2019-07-31
US11046689B2 (en) 2021-06-29
TN2020000009A1 (en) 2021-10-04
PL3494116T3 (pl) 2020-04-30
CR20190379A (es) 2019-10-21
JP6951451B2 (ja) 2021-10-20
ZA201904696B (en) 2020-05-27
PE20191500A1 (es) 2019-10-22
BR112019015389A2 (pt) 2020-03-10
CA3050337A1 (en) 2018-08-02
ES2766249T3 (es) 2020-06-12
LT3494116T (lt) 2020-01-10
US20190233413A1 (en) 2019-08-01
AU2018211495B2 (en) 2020-05-21
TWI794205B (zh) 2023-03-01
PH12019501724A1 (en) 2020-06-01
IL268263B (en) 2021-10-31
US10221173B2 (en) 2019-03-05
SG11201906767XA (en) 2019-08-27
KR20190112767A (ko) 2019-10-07
CL2019001991A1 (es) 2019-10-11
ECSP19062381A (es) 2019-09-30
EP3689873A1 (en) 2020-08-05
AU2018211495A1 (en) 2019-09-12
US10590132B2 (en) 2020-03-17
UA125043C2 (uk) 2021-12-29

Similar Documents

Publication Publication Date Title
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
JOP20190183B1 (ar) معدِلات مستقبلات الاستروجين
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
NZ737399A (en) Ccr2 modulators
MX2019002180A (es) Moduladores alostericos positivos del receptor m1 muscarinico.
CA2912921C (en) Pyrazole compounds as modulators of fshr and uses thereof
MX2021000377A (es) Degradadores selectivos del receptor de estrogeno.
TW201613864A (en) Novel compounds
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
MY161236A (en) (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
NZ763341A (en) Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
WO2015138276A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
NZ741384A (en) Dopamine d3 receptor antagonists having a morpholine moiety
NZ764004A (en) Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
WO2015138280A3 (en) Retinoic acid receptor-related orphan receptor modulators and uses thereof
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
NZ775905A (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
EA201991734A1 (ru) Модуляторы рецептора эстрогена